Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126054013> ?p ?o ?g. }
- W3126054013 abstract "Abstract Background Dolutegravir (DTG)-based antiretroviral therapy (ART) is highly effective and well-tolerated in adults and is rapidly being adopted globally. We describe the design of the ODYSSEY trial which evaluates the efficacy and safety of DTG-based ART compared with standard-of-care in children and adolescents. The ODYSSEY trial includes nested pharmacokinetic (PK) sub-studies which evaluated pragmatic World Health Organization (WHO) weight-band-based DTG dosing and opened recruitment to children < 14 kg while dosing was in development. Methods ODYSSEY (Once-daily DTG based ART in Young people vS. Standard thErapY) is an open-label, randomised, non-inferiority, basket trial comparing the efficacy and safety of DTG + 2 nucleos(t) ides (NRTIs) versus standard-of-care (SOC) in HIV-infected children < 18 years starting first-line ART (ODYSSEY A) or switching to second-line ART (ODYSSEY B). The primary endpoint is clinical or virological failure by 96 weeks. Results Between September 2016 and June 2018, 707 children weighing ≥14 kg were enrolled; including 311 ART-naïve children and 396 children starting second-line. 47% of children were enrolled in Uganda, 21% Zimbabwe, 20% South Africa, 9% Thailand, 4% Europe. 362 (51%) participants were male; median age [range] at enrolment was 12.2 years [2.9–18.0]. 82 (12%) children weighed 14 to < 20 kg, 135 (19%) 20 to < 25 kg, 206 (29%) 25 to < 35 kg, 284 (40%) ≥35 kg. 128 (18%) had WHO stage 3 and 60 (8%) WHO stage 4 disease. Challenges encountered include: (i) running the trial across high- to low-income countries with differing frequencies of standard-of-care viral load monitoring; (ii) evaluating pragmatic DTG dosing in PK sub-studies alongside FDA- and EMA-approved dosing and subsequently transitioning participants to new recommended doses; (iii) delays in dosing information for children weighing 3 to < 14 kg and rapid recruitment of ART-naïve older/heavier children, which led to capping recruitment of participants weighing ≥35 kg in ODYSSEY A and extending recruitment (above 700) to allow for ≥60 additional children weighing between 3 to < 14 kg with associated PK; (iv) a safety alert associated with DTG use during pregnancy, which required a review of the safety plan for adolescent girls. Conclusions By employing a basket design, to include ART-naïve and -experienced children, and nested PK sub-studies, the ODYSSEY trial efficiently evaluates multiple scientific questions regarding dosing and effectiveness of DTG-based ART in children. Trial registration NCT, NCT02259127 , registered 7th October 2014; EUDRACT, 2014–002632-14, registered 18th June 2014 ( https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002632-14/ES ); ISRCTN, ISRCTN91737921 , registered 4th October 2014." @default.
- W3126054013 created "2021-02-01" @default.
- W3126054013 creator A5001333478 @default.
- W3126054013 creator A5006114405 @default.
- W3126054013 creator A5008498385 @default.
- W3126054013 creator A5008927822 @default.
- W3126054013 creator A5009887015 @default.
- W3126054013 creator A5015306937 @default.
- W3126054013 creator A5021568119 @default.
- W3126054013 creator A5023193867 @default.
- W3126054013 creator A5029916608 @default.
- W3126054013 creator A5030021239 @default.
- W3126054013 creator A5030902925 @default.
- W3126054013 creator A5036924989 @default.
- W3126054013 creator A5036926038 @default.
- W3126054013 creator A5037318743 @default.
- W3126054013 creator A5042594419 @default.
- W3126054013 creator A5044248283 @default.
- W3126054013 creator A5045714783 @default.
- W3126054013 creator A5047248287 @default.
- W3126054013 creator A5051559120 @default.
- W3126054013 creator A5059245006 @default.
- W3126054013 creator A5070322756 @default.
- W3126054013 creator A5083468573 @default.
- W3126054013 creator A5083564035 @default.
- W3126054013 creator A5088210610 @default.
- W3126054013 creator A5090095722 @default.
- W3126054013 creator A5091882048 @default.
- W3126054013 date "2021-01-04" @default.
- W3126054013 modified "2023-10-17" @default.
- W3126054013 title "ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing" @default.
- W3126054013 cites W1990925084 @default.
- W3126054013 cites W2048514971 @default.
- W3126054013 cites W2094241860 @default.
- W3126054013 cites W2105813718 @default.
- W3126054013 cites W2122026430 @default.
- W3126054013 cites W2139430929 @default.
- W3126054013 cites W2148924243 @default.
- W3126054013 cites W2167840994 @default.
- W3126054013 cites W2479347439 @default.
- W3126054013 cites W2530271251 @default.
- W3126054013 cites W2565977513 @default.
- W3126054013 cites W2744753912 @default.
- W3126054013 cites W2883284210 @default.
- W3126054013 cites W2884221885 @default.
- W3126054013 cites W2963164305 @default.
- W3126054013 doi "https://doi.org/10.1186/s12879-020-05672-6" @default.
- W3126054013 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7809782" @default.
- W3126054013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33446115" @default.
- W3126054013 hasPublicationYear "2021" @default.
- W3126054013 type Work @default.
- W3126054013 sameAs 3126054013 @default.
- W3126054013 citedByCount "19" @default.
- W3126054013 countsByYear W31260540132021 @default.
- W3126054013 countsByYear W31260540132022 @default.
- W3126054013 countsByYear W31260540132023 @default.
- W3126054013 crossrefType "journal-article" @default.
- W3126054013 hasAuthorship W3126054013A5001333478 @default.
- W3126054013 hasAuthorship W3126054013A5006114405 @default.
- W3126054013 hasAuthorship W3126054013A5008498385 @default.
- W3126054013 hasAuthorship W3126054013A5008927822 @default.
- W3126054013 hasAuthorship W3126054013A5009887015 @default.
- W3126054013 hasAuthorship W3126054013A5015306937 @default.
- W3126054013 hasAuthorship W3126054013A5021568119 @default.
- W3126054013 hasAuthorship W3126054013A5023193867 @default.
- W3126054013 hasAuthorship W3126054013A5029916608 @default.
- W3126054013 hasAuthorship W3126054013A5030021239 @default.
- W3126054013 hasAuthorship W3126054013A5030902925 @default.
- W3126054013 hasAuthorship W3126054013A5036924989 @default.
- W3126054013 hasAuthorship W3126054013A5036926038 @default.
- W3126054013 hasAuthorship W3126054013A5037318743 @default.
- W3126054013 hasAuthorship W3126054013A5042594419 @default.
- W3126054013 hasAuthorship W3126054013A5044248283 @default.
- W3126054013 hasAuthorship W3126054013A5045714783 @default.
- W3126054013 hasAuthorship W3126054013A5047248287 @default.
- W3126054013 hasAuthorship W3126054013A5051559120 @default.
- W3126054013 hasAuthorship W3126054013A5059245006 @default.
- W3126054013 hasAuthorship W3126054013A5070322756 @default.
- W3126054013 hasAuthorship W3126054013A5083468573 @default.
- W3126054013 hasAuthorship W3126054013A5083564035 @default.
- W3126054013 hasAuthorship W3126054013A5088210610 @default.
- W3126054013 hasAuthorship W3126054013A5090095722 @default.
- W3126054013 hasAuthorship W3126054013A5091882048 @default.
- W3126054013 hasBestOaLocation W31260540131 @default.
- W3126054013 hasConcept C126322002 @default.
- W3126054013 hasConcept C142462285 @default.
- W3126054013 hasConcept C187212893 @default.
- W3126054013 hasConcept C197934379 @default.
- W3126054013 hasConcept C203092338 @default.
- W3126054013 hasConcept C2777288759 @default.
- W3126054013 hasConcept C2779502633 @default.
- W3126054013 hasConcept C2993143319 @default.
- W3126054013 hasConcept C3013748606 @default.
- W3126054013 hasConcept C512399662 @default.
- W3126054013 hasConcept C535046627 @default.
- W3126054013 hasConcept C71924100 @default.
- W3126054013 hasConceptScore W3126054013C126322002 @default.
- W3126054013 hasConceptScore W3126054013C142462285 @default.
- W3126054013 hasConceptScore W3126054013C187212893 @default.
- W3126054013 hasConceptScore W3126054013C197934379 @default.